Literature DB >> 2457907

Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli.

D Scandella1, S DeGraaf Mahoney, M Mattingly, D Roeder, L Timmons, C A Fulcher.   

Abstract

Epitopes for antibodies that inhibit factor VIII procoagulant protein were analyzed by deletion mapping of factor VIII protein fragments expressed in Escherichia coli. A human factor VIII cDNA clone was used to generate E. coli expression vectors encoding fragments containing the 80-kDa factor VIII light chain (A3, C1, and C2 domains) and the 44-kDa carboxyl-terminal half of the factor VIII heavy chain (A2 domain). A series of deletions of each fragment was constructed and tested by immunoblotting for the binding of alloantibody and autoantibody inhibitors. Analysis of derivatives of the 80-kDa fragment showed that six inhibitors recognized a major epitope(s) within the carboxyl-terminal 17.3 kDa of factor VIII. These inhibitors also recognized weaker epitopes nearby and one inhibitor recognized epitopes scattered throughout the 80-kDa fragment. Deletions within the heavy chain fragment revealed one epitope-containing region confined to the amino-terminal 18.3 kDa recognized by six inhibitors. Bacterially produced factor VIII fragments containing the major epitopes were capable of neutralizing inhibitors in vitro but fragments containing weaker or no epitopes did not. These data suggest a potential therapeutic use of factor VIII fragments for neutralization of inhibitor antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457907      PMCID: PMC281923          DOI: 10.1073/pnas.85.16.6152

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

3.  Cloning vectors that yield high levels of single-stranded DNA for rapid DNA sequencing.

Authors:  R J Zagursky; M L Berman
Journal:  Gene       Date:  1984-02       Impact factor: 3.688

4.  Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C.

Authors:  F Rotblat; E G Tuddenham
Journal:  Thromb Res       Date:  1981 Feb 15-Mar 1       Impact factor: 3.944

5.  Expression of active human factor VIII from recombinant DNA clones.

Authors:  W I Wood; D J Capon; C C Simonsen; D L Eaton; J Gitschier; B Keyt; P H Seeburg; D H Smith; P Hollingshead; K L Wion; E Delwart; E G Tuddenham; G A Vehar; R M Lawn
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

6.  Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli.

Authors:  E Amann; J Brosius; M Ptashne
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

7.  Heterogeneity of autoantibodies to factor VIII: differences in specificity for apparently distinct antigenic determinants of factor VIII coagulant protein.

Authors:  M P Croissant; M Zuzel; J P Allain
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

8.  Inactivation of factor VIII coagulant activity by two different types of human antibodies.

Authors:  M S Gawryl; L W Hoyer
Journal:  Blood       Date:  1982-11       Impact factor: 22.113

9.  Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide.

Authors:  C A Fulcher; J R Roberts; T S Zimmerman
Journal:  Blood       Date:  1983-04       Impact factor: 22.113

10.  A vector that uses phage signals for efficient synthesis of proteins in Escherichia coli.

Authors:  C Queen
Journal:  J Mol Appl Genet       Date:  1983
View more
  15 in total

1.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

2.  Use of affinity-directed liquid chromatography-mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction.

Authors:  A E Griffiths; W Wang; F K Hagen; P J Fay
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

3.  Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.

Authors:  S H Chen; A R Thompson; M Zhang; C R Scott
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells.

Authors:  Ai-Hong Zhang; Jeongheon Yoon; Yong Chan Kim; David W Scott
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

Review 5.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

Review 6.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

Review 8.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 9.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

10.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.